<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46814344-D2A0-4C3A-920A-598FC35388D4"><gtr:id>46814344-D2A0-4C3A-920A-598FC35388D4</gtr:id><gtr:name>University of W?rzburg</gtr:name><gtr:address><gtr:line1>Pleicherwall 2</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46814344-D2A0-4C3A-920A-598FC35388D4"><gtr:id>46814344-D2A0-4C3A-920A-598FC35388D4</gtr:id><gtr:name>University of W?rzburg</gtr:name><gtr:address><gtr:line1>Pleicherwall 2</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/83E9CAB5-AD40-48DA-8F55-C2C1E70DCC2E"><gtr:id>83E9CAB5-AD40-48DA-8F55-C2C1E70DCC2E</gtr:id><gtr:firstName>Shao-An</gtr:firstName><gtr:surname>Xue</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6853047-0FD9-4830-AAD5-89D341EC087C"><gtr:id>B6853047-0FD9-4830-AAD5-89D341EC087C</gtr:id><gtr:firstName>Hans</gtr:firstName><gtr:surname>Stauss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2C0AE1A4-B497-4343-8EE8-FD98C852AC55"><gtr:id>2C0AE1A4-B497-4343-8EE8-FD98C852AC55</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/83A23F6E-CC5B-4654-A784-6D22114FB5F4"><gtr:id>83A23F6E-CC5B-4654-A784-6D22114FB5F4</gtr:id><gtr:firstName>Max</gtr:firstName><gtr:surname>Topp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0902209"><gtr:id>F1CB4C6E-3184-46A1-BEC6-6B120E5A37EB</gtr:id><gtr:title>Development of Adoptive immunotherapy of EBV-associated Malignancies by Retroviral LMP2-TCR Gene Transfer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902209</gtr:grantReference><gtr:abstractText>Epstein Barr Virus (EBV) can cause several different types of cancer. There are currently no treatments available for some of these cancers. Our proposal is to take blood cells from patients with EBV-associated cancer and turn them into killer cells directed towards the cancer cells and then inject back into the patient. These killer cells will then be able to destroy the cancer cells and cure the patient.</gtr:abstractText><gtr:technicalSummary>Latent membrane protein-2 (LMP2) is an Epstein Barr Virus (EBV)-derived antigen that is expressed in approximately 40% of lymphomas, 10% gastric carcinomas and virtually all undifferentiated non-keratinising nasopharyngeal carcinomas (NPC) with poor prognosis. We propose to develop T cell receptor (TCR) gene therapy to generate LMP2-specific T cell populations for the treatment of EBV-associated lymphomas, gastric cancer and NPC. We have recently isolated the genes encoding the alpha and beta chain of a high avidity LMP2-specific TCR. The aim of the project will be to demonstrate that TCR-gene transfer efficiently generates LMP2-specific CD4+ and CD8+ T cell populations that are capable recognising tumour cells expressing LMP2 endogenously. Successful completion of the project will form the basis of a Phase I/II clinical trial in patients.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>278244</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Manchester</gtr:department><gtr:description>ATTRACT</gtr:description><gtr:id>6C3FB68D-CF9B-495E-AB57-1EC1C4AE3611</gtr:id><gtr:impact>appointment of a PhD student</gtr:impact><gtr:partnerContribution>This is an EU funded project coordinated from Manchester</gtr:partnerContribution><gtr:piContribution>We provide research and training expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich (Universit?t Z?rich UZH)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Immunotherapy in NSG mice</gtr:description><gtr:id>0E36D86A-63D2-4242-A2E0-706BC2AD0E61</gtr:id><gtr:impact>Grant application to LLR.</gtr:impact><gtr:partnerContribution>Zurich provides expertise in the NSG animal model.</gtr:partnerContribution><gtr:piContribution>In this collaboration, we explore T Cell therapy of EBV tumors. We provide the T Cell expertise/reagents and Prof. Munz the animal model.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of W?rzburg (Universit?t W?rzburg)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Wuerzburg Collaboration</gtr:description><gtr:id>2D1A31AA-7C5D-4815-9130-88F5B56CE862</gtr:id><gtr:impact>Our collaborator Prof Topp is co-applicant on this grant</gtr:impact><gtr:partnerContribution>Provision of cells used for TCT cloning</gtr:partnerContribution><gtr:piContribution>We have isolated the TCR genes that are used in this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public Lecture on T Cell therapy.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8668FA86-896F-425E-A672-037AC28BD95E</gtr:id><gtr:impact>Approximately 200 lay people attended lecture on T Cell therapy.

Lecture was recorded and is available on You-tube.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=uVJu3RJ1QSk</gtr:url><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit Primrose Hill</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>ADC67135-2E44-4CE8-B8A8-1312B20CD4B7</gtr:id><gtr:impact>Parents attended a presentation of our research and all children attended an assembly

Children raised funds to support cancer research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>B27BFB12-3723-4D20-B95C-85496F431161</gtr:id><gtr:impact>Parents attended the presentation which was followed by a lively discussion, and some individuals wanting to donate money for research.

School asked me to come back for a second presentation.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>256000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>555DF669-D408-4DA4-B225-4CBBFE9DEB86</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2418108</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>146D17F6-0D12-48FE-BF97-06C2EB0B06C0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230607</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6ECE608A-35AF-451B-B7ED-80A869CBB6E0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>253094</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2482AC55-E4CF-489E-8C14-79ECB115EEA5</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1895702</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Program Grant</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>B620D889-5E07-471A-97FB-64B7E837F2FF</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The LMP2-TCR may be used for TCR gene therapy of lymphoma and nasopharyngeal carcinoma. A patent has been filed for the theurapeutic exploitation of the LMPC-TCR.</gtr:description><gtr:id>690BC010-BAA2-4BEE-B45B-5C9865237617</gtr:id><gtr:impact>Strong platform for commercial interactions</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2011039508</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>LMP2-TCR</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>TCR genes validated. Next step is a clinical trial.</gtr:description><gtr:id>BB6251D1-DA8A-4DD7-A902-D4FEB628DCDD</gtr:id><gtr:impact>The TCR genes have been patented</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>LMP2-TCR</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The function of gene modified T cells was enhanced by co-transfer of TCR and single chain FV constructs to mediate co-stimulation.</gtr:description><gtr:id>120F134F-2020-4C67-8CED-157AABF8DA31</gtr:id><gtr:impact>The developed technology may enhance the efficacy and specificity of TCR gene therapy</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Gene engineered T cells</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A18D01F-A4DA-46E9-89AC-EFFB5463F73F"><gtr:id>2A18D01F-A4DA-46E9-89AC-EFFB5463F73F</gtr:id><gtr:title>Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d157d955438798b538137bcea2905be3"><gtr:id>d157d955438798b538137bcea2905be3</gtr:id><gtr:otherNames>Pospori C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/310EE774-4986-4AC5-9EAE-894AE01D494B"><gtr:id>310EE774-4986-4AC5-9EAE-894AE01D494B</gtr:id><gtr:title>Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed997fbf0d6912b0d8a0798c8f82bb86"><gtr:id>ed997fbf0d6912b0d8a0798c8f82bb86</gtr:id><gtr:otherNames>Gilham DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A6BFA06-B902-422A-AD7C-9AC23C9BC2A9"><gtr:id>4A6BFA06-B902-422A-AD7C-9AC23C9BC2A9</gtr:id><gtr:title>Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c31326fe2d7119af01381f29a5e77427"><gtr:id>c31326fe2d7119af01381f29a5e77427</gtr:id><gtr:otherNames>Thomas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A93427AF-A148-4A83-9356-38FADE9BBBCC"><gtr:id>A93427AF-A148-4A83-9356-38FADE9BBBCC</gtr:id><gtr:title>Cancer gene therapy with T cell receptors and chimeric antigen receptors.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad7f303a3a2d1f7ece5a892a3c32ad92"><gtr:id>ad7f303a3a2d1f7ece5a892a3c32ad92</gtr:id><gtr:otherNames>Stauss HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98BCE3E6-0AA3-44D3-95BA-EFD9BCB335BD"><gtr:id>98BCE3E6-0AA3-44D3-95BA-EFD9BCB335BD</gtr:id><gtr:title>Improving TCR Gene Therapy for Treatment of Haematological Malignancies.</gtr:title><gtr:parentPublicationTitle>Advances in hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ae2a25850360f65ec63f35761b26fa8"><gtr:id>1ae2a25850360f65ec63f35761b26fa8</gtr:id><gtr:otherNames>Nicholson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80688E49-05C6-48F4-BCD4-5E0A26C16666"><gtr:id>80688E49-05C6-48F4-BCD4-5E0A26C16666</gtr:id><gtr:title>Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ae03fe329f6f39f6142945d9f563e49"><gtr:id>6ae03fe329f6f39f6142945d9f563e49</gtr:id><gtr:otherNames>Xue SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3B71EE5-21D9-4F7D-807F-CFD50331810E"><gtr:id>E3B71EE5-21D9-4F7D-807F-CFD50331810E</gtr:id><gtr:title>CD3 limits the efficacy of TCR gene therapy in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0f765284859075e7bd4dc6527aba8b88"><gtr:id>0f765284859075e7bd4dc6527aba8b88</gtr:id><gtr:otherNames>Ahmadi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BADB658-DBFF-4A1B-AD81-98D72FBFB753"><gtr:id>3BADB658-DBFF-4A1B-AD81-98D72FBFB753</gtr:id><gtr:title>Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f8dc2ebc70eda0b46fe7ca7cb568be2"><gtr:id>7f8dc2ebc70eda0b46fe7ca7cb568be2</gtr:id><gtr:otherNames>Gehring AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70FC0548-4867-4B4F-BDA3-D4E11F779585"><gtr:id>70FC0548-4867-4B4F-BDA3-D4E11F779585</gtr:id><gtr:title>Molecular immunology lessons from therapeutic T-cell receptor gene transfer.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c31326fe2d7119af01381f29a5e77427"><gtr:id>c31326fe2d7119af01381f29a5e77427</gtr:id><gtr:otherNames>Thomas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA624A68-C60F-4FDA-8A60-17612EB818A7"><gtr:id>BA624A68-C60F-4FDA-8A60-17612EB818A7</gtr:id><gtr:title>CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/54f9e3e773c769e589346684ebee8e7e"><gtr:id>54f9e3e773c769e589346684ebee8e7e</gtr:id><gtr:otherNames>Ghorashian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75F3FBF0-D76F-471E-AF7D-F610C2AFFFF5"><gtr:id>75F3FBF0-D76F-471E-AF7D-F610C2AFFFF5</gtr:id><gtr:title>Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6fddbee7fc8ebee4cdd6e609fe63ce53"><gtr:id>6fddbee7fc8ebee4cdd6e609fe63ce53</gtr:id><gtr:otherNames>Holler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6A00CBB-A56C-455C-B707-D7A1BAD57B2E"><gtr:id>D6A00CBB-A56C-455C-B707-D7A1BAD57B2E</gtr:id><gtr:title>Engineered T cells can fight malignant T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad7f303a3a2d1f7ece5a892a3c32ad92"><gtr:id>ad7f303a3a2d1f7ece5a892a3c32ad92</gtr:id><gtr:otherNames>Stauss HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D936D3B-0796-4DF9-9A65-706FC60F65F9"><gtr:id>4D936D3B-0796-4DF9-9A65-706FC60F65F9</gtr:id><gtr:title>Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bd2ca761a141ca7db238491b9127a7d8"><gtr:id>bd2ca761a141ca7db238491b9127a7d8</gtr:id><gtr:otherNames>Qasim W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902209</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>